Oramed Pharmaceuticals vs Rafael
ORMP and RFL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ORMP and RFL compare
Oramed Pharmaceuticals is the larger company, worth 2.8 times as much as Rafael ($154M against $55.8M).
Oramed Pharmaceuticals pays a dividend yielding 6.7%; Rafael does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 5 for Rafael), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ORMP | RFL |
|---|---|---|
| Size and price | ||
| Market cap | $154M | $55.8M |
| Share price | $3.71 | $1.07 |
| Change, 1 year | 50.2% | −15.7% |
| Change, 5 years | −86.0% | −82.4% |
| Beta (5Y) | 1.42 | 0.84 |
| Employees | 13 | 17 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 2 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 1.1× | – |
| P/S | – | 63.9× |
| P/B | – | 0.8× |
| PEG | 0.04 | – |
| FCF yield | −2.1% (better) | −53.7% |
| Growth | ||
| Revenue growth (TTM) | – | −4.7% |
| Revenue growth, 5Y average | −5.8% | 1.7% (better) |
| Net income growth (TTM) | 230% | – |
| EPS growth (TTM) | 241% | – |
| EPS growth, 5Y average | 12.8% | – |
| Profitability | ||
| Operating margin | – | −3823% |
| Net margin | – | −3391% |
| FCF margin | – | −3431% |
| Return on equity | 71.3% (better) | −36.9% |
| Return on invested capital | −8.5% (better) | −61.5% |
| Financial health | ||
| Interest coverage | – | −100.3× |
| Current ratio | 6.07 (better) | 2.35 |
| Altman Z-score | 1.55 (better) | −2.49 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 6.7% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 6.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 40.3% | 7.5% |
| Held by insiders | 23.9% | 39.2% |
| Insider net buying, 12 months | −$1.2M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.2% | 0.92% |
Go deeper
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
- RFL stock overview
- RFL income statement
- RFL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.